Physician profile
Melissa Mannion
NPI 1164683439
$1,989.34
in general payments reported to CMS, 2019-2025
12 companies · $105 in 2025
The $105 reported for 2025 was less than what a typical Pediatric Rheumatology provider received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,118 · 2020: $371 · 2022: $125 · 2023: $148 · 2024: $122 · 2025: $105.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $375.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $375.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $555.74 | 2019-2025 | |
| Abbvie INC. | $419.66 | 2019-2023 | |
| Glaxosmithkline, LLC. | $382.09 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $169.26 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $125.00 | 2022 | |
| Ucb, INC. | $125.00 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $121.86 | 2019 | |
| Mallinckrodt Enterprises LLC | $23.53 | 2019 | |
| Novartis Pharmaceuticals Corporation | $18.90 | 2019 | |
| Antares Pharma, INC. | $16.81 | 2019 | |
| Sobi, INC | $16.35 | 2020 | |
| Silvergate Pharmaceuticals, INC. | $15.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Mannion listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.